Search results
5-PLASMA TAFI Deficient Plasma, frozen
For any in vitro protocol or research study where a source of human TAFI deficient plasma is required.
BIOPHEN Heparin anti-IIa (2-stages kit)
Assay proposed for the measurement of heparin anti-thrombin activity in research applications acc. to Pharmacopoeia.
HEMOCLOT LA-C (Confirm)
Reagent with low phospholipid concentration for confirming the presence of lupus anticoagulants (LA). The presence of LA does not or only insignificantly prolong clotting time.
HEMOCLOT LA-S (Screen)
Reagent with low phospholipid concentration for lupus anticoagulants (LA) determination. The presence of LA prolongs clotting time.
NAPTT Reagent Kit
Liquid "ready for use", containing synthetic phospholipid blend. This kit is intended for use in the European Pharmacopoeia (EP) method for the detection of activated coagulation factors in therapeutic products. Also, the NAPTT reagent alone can be used in the NAPTT test for detecting contact activation and hypercoagulability (For Research Use Only).
Heparin testing according to EP/USP/FDA
New immunoturbidimetric assays for:
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 2.5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.